AbbVie confirmed its $11 billion acquisition of Apogee Therapeutics, enhancing its drug pipeline in immunology, oncology, neuroscience, and aesthetics. The deal causes only modest near-term earnings dilution. AbbVie's Q2 results beat expectations, driven by strong sales of Skyrizi and Rinvoq. The company remains a 'Buy' due to solid fundamentals and attractive valuation, though risks include competition and clinical trial outcomes. Upcoming industry events may cause short-term volatility, but momentum points to a price target of $292.
Retirees are increasingly turning to high-yield dividend stocks from diverse industries to supplement income beyond Social Security's fixed cost-of-living adjustments. Stocks like Verizon, Altria, AbbVie, Realty Income, and Enbridge offer yields from...
AbbVie has partnered with McLaren Racing as an Official Pharmaceutical Partner, launching the Race to Innovate campaign at the 2026 U.S. Grand Prix. For every 10 Constructors' Championship points McLaren earns, AbbVie will donate $10,000 to global ch...
In a Phase 2a study, ABBV-466, a dual-targeting therapy by AbbVie, achieved significantly higher endoscopic remission rates in Crohn's disease patients at Week 12 compared to anti-IL-23 p19 or anti-α4β7 monotherapies. The remission advantage increase...
At the 2026 European Society for Medical Oncology (ESMO) Congress, AbbVie presented new and updated data on its oncology portfolio, including investigational drugs like Temab-A, ABBV-706, and ABBV-969. These drugs showed encouraging clinical activity...
AbbVie increased its quarterly dividend to $1.73, raising its annual payout by 5.5% despite a 29% stock price rise this year, which lowers the yield to about 2.4%. The company’s dividend payout ratio is around 49.5% of adjusted earnings, supported by...
